CTLA4 and neoplasm: Kuai et al.149 recently reported that the use of this nanocarrier technology in a murine colon adenocarcinoma model generated a robust neoantigen-specific CD8+ T-cell response resulting in complete inhibition of tumor growth; additionally, concomitant vaccination with dual PD-1 and CTLA-4 blockade led to complete tumor regression in approximately 90% of mice.